

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	3Q `08	3Q `07	YTD 2008	YTD 2007
MERCK / SCHERING-PLOUGH	\$ 400.2	\$ 480.9	\$ 1,158.2	\$ 1,293.1
ASTRAZENECA LP	139.1	181.2	331.6	608.3
Other ⁽¹⁾	126.3	106.4	350.9	278.8
TOTAL	\$ 665.6	\$ 768.5	\$ 1,840.7	\$ 2,180.2

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & Johnson^oMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

Merial	3Q `08	3Q `07	YTD 2008	YTD 2007
FRONTLINE, other fipronil	\$ 253.3	\$ 241.7	\$ 901.0	\$ 866.1
BIOLOGICALS	198.0	162.0	580.9	472.8
IVOMEK, HEARTGARD, other avermectins	128.6	112.8	415.0	366.7
Other Animal Health	72.1	66.7	220.8	192.0
TOTAL MERIAL SALES	\$ 652.0	\$ 583.2	\$ 2,117.7	\$ 1,897.6

Sanofi Pasteur-MSD	3Q `08	3Q `07	YTD 2008	YTD 2007
GARDASIL	\$ 220.1	\$ 137.0	\$ 694.1	\$ 245.0
VIRAL VACCINES	28.9	20.7	80.7	65.0
HEPATITIS VACCINES	19.3	18.0	56.7	53.9
Other Vaccines	298.5	263.6	576.7	535.0
TOTAL SANOFI PASTEUR-MSD SALES	\$ 566.8	\$ 439.3	\$ 1,408.2	\$ 898.9

Merck / Schering-Plough Collaboration	3Q `08	3Q `07	YTD 2008	YTD 2007
VYTORIN	\$ 567.2	\$ 693.0	\$ 1,810.5	\$ 2,003.2
ZETIA	534.3	607.0	1,676.4	1,728.5
TOTAL MERCK / SCHERING-PLOUGH SALES	\$ 1,101.5	\$ 1,300.0	\$ 3,486.9	\$ 3,731.7

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	3Q `08	3Q `07	YTD 2008	YTD 2007
INTEREST INCOME	\$ (171.3)	\$ (186.9)	\$ (484.2)	\$ (540.9)
INTEREST EXPENSE	71.4	91.5	194.6	297.2
EXCHANGE LOSSES (GAINS)	52.3	(8.3)	73.6	(39.8)
MINORITY INTERESTS	31.2	30.6	93.9	92.0
Other, net ⁽¹⁾	78.2	(107.8)	(2,075.3)	(329.7)
TOTAL	\$ 61.8	\$ (180.9)	\$ (2,197.4)	\$ (521.2)

⁽¹⁾ Other, net for the first nine months of 2008 primarily reflects a gain of \$2.2 billion related to a distribution from AstraZeneca LP.

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2008

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	3Q '08 vs. 3Q '07					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	9%	888	4%	314	12%	574
FOSAMAX	-51%	354	-80%	96	1%	258
SINGULAIR	1%	1,029	-4%	692	12%	337
Vaccines:						
GARDASIL	-4%	401	-16%	276	37%	125
ROTATEQ	-21%	134	-23%	125	-4%	10
ZOSTAVAX	-82%	11	-82%	11	N/A	-
OTHER VIRAL VACCINES ⁽¹⁾	-	430	-2%	404	66%	27
HEPATITIS VACCINES ⁽²⁾	-47%	36	-56%	25	-2%	11
OTHER VACCINES ⁽³⁾	-17%	81	-40%	47	86%	34
Other Reported Products:						
ARCOXIA	27%	97	N/A	-	27%	97
CANCIDAS	9%	148	-30%	24	23%	124
COSOPT / TRUSOPT	6%	209	-	86	11%	123
CRIVAN / STOCRIN	-5%	69	-33%	3	-3%	65
EMEND	40%	68	33%	44	53%	24
INVANZ	43%	71	38%	37	50%	34
ISENTRESS	*	107	*	57	*	51
JANUVIA	*	379	74%	297	*	82
JANUMET	*	101	*	86	*	14
MAXALT	9%	136	8%	93	11%	43
PRIMAXIN	1%	188	-32%	32	12%	155
PROPECIA	9%	108	2%	39	13%	69
PROSCAR	-10%	81	-57%	3	-5%	77
TIMOPTIC / TIMOPTIC XE	5%	30	-	2	6%	28
VASOTEC / VASERETIC	-31%	82	N/A	-	-31%	82
ZOCOR	-28%	157	-69%	17	-14%	140
ZOLINZA	32%	4	29%	4	N/A	-

* 100% or over
N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta.

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	3Q '08	% CHG	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	\$ 5,944	-2%	-6	=	4
U.S. (\$ MM)	3,337	-11%	-14	3	N/A
Foreign (\$ MM)	2,607	13%	6	-3	10

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SEPTEMBER YEAR-TO-DATE
2008

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	SEPTEMBER YTD '08 vs. SEPTEMBER YTD '07					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	9%	2,676	2%	928	13%	1,748
FOSAMAX	-45%	1,235	-71%	422	3%	813
SINGULAIR	3%	3,215	-4%	2,116	20%	1,098
Vaccines:						
GARDASIL	-2%	1,117	-11%	824	36%	293
ROTATEQ	34%	502	32%	470	77%	32
ZOSTAVAX	-	151	-	151	N/A	-
OTHER VIRAL VACCINES ⁽¹⁾	-4%	974	-7%	896	49%	77
HEPATITIS VACCINES ⁽²⁾	-51%	108	-57%	79	-15%	29
OTHER VACCINES ⁽³⁾	-22%	223	-49%	109	59%	113
Other Reported Products:						
ARCOXIA	20%	294	N/A	-	20%	294
CANCIDAS	13%	457	-25%	80	27%	378
COSOPT / TRUSOPT	9%	627	-	254	16%	374
CRIXIVAN / STOCRIN	-3%	223	-36%	10	-1%	213
EMEND	35%	193	24%	125	60%	69
INVANZ	43%	197	31%	99	58%	98
ISENTRESS	*	231	*	131	*	100
JANUVIA	*	984	*	786	*	198
JANUMET	*	232	*	209	*	23
MAXALT	14%	388	12%	257	17%	131
PRIMAXIN	4%	592	-22%	124	14%	467
PROPECIA	9%	321	-	113	15%	207
PROSCAR	-23%	252	-82%	10	-12%	242
TIMOPTIC / TIMOPTIC XE	3%	91	-10%	5	4%	85
VASOTEC / VASERETIC	-26%	271	N/A	-	-26%	271
ZOCOR	-22%	513	-49%	64	-15%	449
ZOLINZA	32%	11	25%	10	*	1

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta.

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	SEP YTD '08	% CHG	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	\$ 17,818	-1%	-4	-1	4
U.S. (\$ MM)	9,974	-9%	-10	1	N/A
Foreign (\$ MM)	7,844	12%	6	-4	11